Prevalence of HPV and genotype distribution in “catch-up” HPV vaccinated women

Purpose of investigation: The aim of the present study was to evaluate the prevalence of HPV and genotype distribution among HPVvaccinated women. Material and Methods: The authors recruited 147 women, which were vaccinated through “catch-up vaccination”, five years before this study. The authors analyzed the presence of HPV, genotype distribution, and risk factors for HPV infections. Results: The relative prevalence of HPV/DNA was as follows: out of the total 147 tested samples, 19 samples (12.92%) were positive for HPV/DNA, 11 of which (7.48%) were single type HPV infections, and eight (5.44%) tested positive for multiple HPV genotypes. The most frequent genotypes were: 16, followed by 35, 56, and 31. Low risk genotypes 6 and 11 were present together in one case. Conclusion: The results showed a decrease in HPV prevalence 16/18 in vaccinated women through a catch-up vaccination, suggesting good effects of the previous HPV immunization program.

HPV infection; HPV vaccine; “Catch-up” vaccination.

[1] Wheeler C.M., Castellsague X., Garland S.M. Szarewski A., Paavonen J., Naud P., et al.: “Cross-protective efficacy of hpv-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by nonvaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind Patricia trial”. Lancet Oncol., 2012, 13, 100.

[2] Tota J.E., Chevarie-Davis M., Richardson L.A., Devries M., Franco E.L.: “Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies”. Prev. Med., 2011, 53, S12.

[3] Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertig D.M.: “Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study”. Lancet, 2011, 377, 2085.

[4] Tabrizi S.N., Brotherton J.M., Kaldor J.M., Skinner S.R., Cummins E., Liu B., et al.: “Fall in human papillomavirus prevalence following a national vaccination program”. J. Infect. Dis., 2012, 206, 1645.

[5] Craciun C., Baban A.: “Who will take the blame?: understanding the reasons why Romanian mothers decline HPV vaccination for their daughters”. Vaccine, 2012, 30, 6789.

[6] Dorleans F., Giambi C., Dematte L., Cotter S., Stefanoff P., Mereckiene J., et al: “The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey”. Euro. Surveill., 2010, 15, 47.

[7] Kjaer S.K., Breugelmans G., Munk C., Junge J., Watson M., Iftner T.: “Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark”. Int. J. Cancer, 2008, 123, 1864.

[8] Hariri S., Unger E.R., Sternberg M., Dunne E.F., Swan D., Patel S., et al.: “Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006”. J. Infect. Dis., 2011, 204, 566.

[9] Socolov G., Anton G., Anton E., Teleman S., Anton A.C., Carauleanu A., et al.: “Human papilloma virus distribution in patients from Moldova region”. Gineco.ro., 2008, 4, 248.

[10] Ursu R.G., Onofriescu M., Nemescu D., Iancu L.S.: “HPV prevalence and type distribution in women with or without cervical lesions in the Northeast region of Romania”. Virol. J., 2011, 22, 558.

[11] Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al.: “Effect of human papillomavirus 16/18 L1 virus like particle vaccine among young women with preexisting infection: a randomized trial”. JAMA, 2007, 29, 743.

[12] Garland S.M., Hernandez-Avila M., Wheeler C.M, Perez G., Harper D.M., Leodolter S., et al.: “Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases”. N. Engl. J. Med., 2007, 10, 1928.

[13] Mzarico E., Gómez-Roig D., Guirado L., Lorente N., GonzalezBosquet E.: “Relationship between smoking, HPV infection, and risk of cervical cancer”. Eur. J. Gynaecol. Oncol., 2015, 36, 677.

[14] Collins S., Rollason T.P., Young L.S., Woodman C.B.: “Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: a longitudinal study”. Eur. J. Cancer. 2010, 46, 405.

[15] Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S. et al.: “Prevalence of HPV infection among females in the United States”. JAMA, 2007, 297, 813.

[16] Monsonego J.: “Current direction in the prevention of cervical cancer”. Eur. J. Gynaecol. Oncol., 2007, 28, 433.